Unique ID issued by UMIN | UMIN000003802 |
---|---|
Receipt number | R000004376 |
Scientific Title | Efficacy and safety of 4-phenylbutyrate in refractory cholestatic disease including progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and Alagille syndrome. |
Date of disclosure of the study information | 2010/06/22 |
Last modified on | 2015/04/22 10:47:35 |
Efficacy and safety of 4-phenylbutyrate in refractory cholestatic disease including progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and Alagille syndrome.
Efficacy and safety of 4-phenylbutyrate in refractory cholestatic disease including progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and Alagille syndrome.
Efficacy and safety of 4-phenylbutyrate in refractory cholestatic disease including progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and Alagille syndrome.
Efficacy and safety of 4-phenylbutyrate in refractory cholestatic disease including progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and Alagille syndrome.
Japan |
Progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and Alagille syndrome.
Hepato-biliary-pancreatic medicine | Pediatrics |
Others
NO
Efficacy and safety of 4-phenylbutyrate in refractory cholestatic disease including progressive familial intrahepatic cholestasis, primary biliary cirrhosis, primary sclerosing cholangitis and Alagille syndrome.
Safety,Efficacy
subjective and objective symptom (pruritus, jaundice)
T-Bil, D-Bil, AST, ALT, LDH, ALP, TBA, urine pH, glucose, occult blood, bilirubin, urobilinogen.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
phenylbutyrate(Child 250mg/kg/day)for 1-4months : phenylbutyrate(Child 350mg/kg/day)for 1-4months : phenylbutyrate(Child 500mg/kg/day)for 1-4months
Not applicable |
Not applicable |
Male and Female
Patients with caretaker's approval
History of drug hypersensitivity
Severe liver injury
Renal function impairment
Severe complication
Poor medical compliance
15
1st name | |
Middle name | |
Last name | Ayano Inui |
Saiseikai Yokohama City Tobu Hospital
Division of Hepatology and Gastroenterology, Children's Center for Health and Development
3-6-1 Shimosueyoshi Tsurumi-ku, Yokohama City, Kanagawa
(045)576-3000
a_murayama@yobu.saiseikai.or.jp
1st name | |
Middle name | |
Last name | Ayano Inui |
Saiseikai Yokohama City Tobu Hospital
Division of Hepatology and Gastroenterology, Children's Center for Health and Development
3-6-1 Shimosueyoshi Tsurumi-ku, Yokohama City, Kanagawa
(045)576-3000
a_murayama@yobu.saiseikai.or.jp
Saiseikai Yokohama City Tobu Hospital
MEXT scientific research fund
Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo (Tokyo)
MEXT scientific research fund
NO
済生会横浜市東部病院(神奈川県), Saiseikai Yokohamashi Tobu Hospital (Kanagawa)
大阪大学医学部附属病院(大阪府), Osaka University Hospital (Osaka)
獨協医科大学越谷病院(埼玉県), Dokkyo Medical University, Koshigaya Hospital (Saitama)
岩手医科大学病院(岩手県), Iwate Medical University (Iwate)
2010 | Year | 06 | Month | 22 | Day |
Unpublished
Enrolling by invitation
2010 | Year | 04 | Month | 01 | Day |
2010 | Year | 04 | Month | 01 | Day |
2010 | Year | 06 | Month | 22 | Day |
2015 | Year | 04 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004376